Skip To Main Content
Jean-Sélim Driouich on Muck Rack

Jean-Sélim Driouich

As seen in: Nature, Wiley Online Library, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jean-Sélim

Contact Jean-Sélim, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Assessing Human Liver Spheroids as a Model for Antiviral Drug Evaluation Against BSL-3 Haemorrhagic Fever viruses

|
By Sarah Chaput, Jean-Sélim Driouich, Xavier de Lamballerie, Antoine Nougairède
| BioRxiv
Abstract Haemorrhagic fever viruses (HFVs) cause highly lethal syndromes with limited therapeutic options. Increasingly, 3D cell culture models are becoming an important tool in the field of virology. Since the liver is an important target for many HFVs, we evaluated a ready-to-use 96-well liver spheroid model composed of human primary cells for antiviral assessment.
Open in Who Shared Issue with article?

In vivo rescue of arboviruses directly from subgenomic DNA fragments

|
By Maxime Cochin, Jean-Sélim Driouich, Grégory Moureau, Géraldine Piorkowski
| BioRxiv
Abstract Reverse genetic systems are mainly used to study RNA viruses and rescue recombinant strains in cell culture. Here, we provide proof-of-concept for direct in vivo viral generation using the 'Infectious Subgenomic Amplicons' method. So far, this procedure allowed to rescue in vitro RNA viruses, by the transfection of several overlapping subgenomic DNA fragments encoding the entire virus genome.
Open in Who Shared Issue with article?

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

|
By Jean-Sélim Driouich, Raphaelle Klitting, Ornellie Bernadin, Hawa Sophia Bouzidi
| BioRxiv
Abstract Since the start of the SARS-CoV-2 pandemic, the search for antiviral therapies has been at the forefront of medical research. To date, the 3CLpro inhibitor nirmatrelvir (Paxlovid) has shown the best results in clinical trials and the greatest robustness against variants. A second SARS-CoV-2 protease inhibitor, ensitrelvir (Xocova), has been developed.
Open in Who Shared Issue with article?
See all 6 articles